Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

  • Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24 on a day volume of 610.52 thousand shares, closed regular trading session at $4.07. The company shares are currently trading at $4.2, up 3.19 percent in the after-hours trading session.
  • NexImmune (NASDAQ:NEXI) has received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, its first solid tumor product candidate for the treatment of HPV-related cancers. NexImmune shares traded in a range of $1.25 to $1.33 on a day volume of 59.94 thousand shares, closed regular trading session at $1.26. The company shares are currently trading at $1.3, up 3.17 percent in the after-hours trading session.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.